Cassava Sciences (MEX:SAVA) Tax Provision : MXN0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cassava Sciences Tax Provision?

Cassava Sciences's tax provision for the three months ended in Mar. 2024 was MXN0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2024 was MXN0.00 Mil.

Cassava Sciences Tax Provision Historical Data

The historical data trend for Cassava Sciences's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cassava Sciences Tax Provision Chart

Cassava Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Tax Provision

Get a 7-Day Free Trial

Cassava Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Cassava Sciences Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.00 Mil.

Cassava Sciences (MEX:SAVA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cassava Sciences Inc (MEX:SAVA) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

SAVA:USA PX91:Germany

Address

6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731

Website

https://www.cassavasciences.com

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.